Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...
Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...